Investor Presentaiton

FY 2022/23 guidance - organic growth of around 8% and reported EBIT margin of 28-29%¹ GUIDANCE 2022/23 GUIDANCE (DKK)* 14 KEY ASSUMPTIONS • Chronic Care ex. China expected to grow largely in line with Strive25 ambitions: Europe - continued good momentum; US - sustained good momentum in Ostomy Care and improvement in growth in Continence Care; Emerging markets - broad based double-digit growth ex. China • Wound and Skin Care - growth above market in line with Strive25 ambitions • SALES GROWTH . Around 8% 8-9% • • • . • • China (OC and WC) - impact from COVID-19 in H1 2022/23, and improvement in growth in H2 2022/23, driven by a lower baseline last year, as well as the normalisation in hospital access and procedural volumes in Q3. The average value per patient in Ostomy Care is expected to remain below pre-COVID levels Interventional Urology - expected to grow around 10% Voice & Respiratory Care - expected to grow at 8-10% (8 months impact on organic growth) Russia - revenue expected to be on par with FY 2021/22 (1% of group revenue) with negative growth No current knowledge of significant healthcare reforms; positive pricing impact expected Stable supply and distribution of products - backorder impact in Collecting Devices in H1 2022/23 and Wound Care in the first nine months of 2022/23 Reported growth in DKK assumes negative impact from currencies of around 2%-points and around 3%-points contribution from the Atos Medical acquisition (4 months impact) Increased input cost: raw materials - double-digit price increase, energy costs - ca. double vs. 2021/22, double-digit wage increase in Hungary • EBIT MARGIN Negative impact from currencies 28-29% . (before special items) • Leverage effect on fixed costs and continued efficiency improvements through GOP5 Prudent management of OPEX - expected to grow below reported revenue growth (excl. acquired growth) Amortisation charges related to the Atos Medical acquisition of around DKK 220 million CAPEX (DKKm) TAX RATE • Special items of around DKK 50 million¹ • Around 1.3bn Investments in automation at volume sites in Hungary and China as part of GOP5 Investments in new machines for existing and new products • IT and sustainability investments • Atos Medical capex and integration capex Around 21% • Positive (one-off) impact from Atos Medical IP transfer *DKK guidance is based on spot rates as of 15 August 2023 1 Before special items. Around DKK 50 million in special items expenses expected in FY 2022/23, of which income of DKK 244 million related to Atos Medical billing provision reversal, DKK 200 million expense related to the Mesh litigations, around DKK 50 million expense related to integration of Atos Medical, and around DKK 50 million transaction related expense from the acquisition of Kerecis (advisory fees). Coloplast

View entire presentation